AKT1 and ovarian carcinoma: In doxorubicin-resistant ovarian carcinoma cells, BCRP overexpression was mediated by the c-MET elevation and resultant PI3K/AKT activation, and thus, the inhibition of c-MET could repress the plasma membrane BCRP level and enhanced doxorubicin-induced cell death.